Avid Bioservices Inc (CDMO)

[entdoc]

the other guy, the question (at least to me) is not whether radioactive iodine is cancercidal and a good treatment modality (it is), but whether and what type of MAB is necessary to deliver it. If you have to place a catheter into the cerebral spinal fluid space, thread it up to the tumor, or put a hole in the skull to thread the catheter into the subarachnoid space...and then penetrate the tumor...and then deliver the I-131, do you really ned a monoclonal antibody to deliver it!?! The point is to find a MAB that will cross the blood-brain barrier (almost an oxymoron). "Homing-in on the -PS of the tumor vasculature with Bavi ,and then lobbing the tumorcidal agent at tumor interior...AND surface...is what makes sense. I can see stopping GBM dead in its tracks that way. But so far we have made all the wrong choices for clinical trials: Chemo- + Bavi instead of Irradiation + Bavi. AND THEN we move toward immune-oncology...I-O...upstream...downstream...it's all the same. So Bavi is weakly immunogenic. Another unfortunate observation for us. Hopefully it will be weakly helpful immunologically too when they finally figure out the right application for Bavi. And I believe that sooner or later PPHM, or someone, will get it right.